AR-701 (Aridis Pharmaceuticals)

N/A

Report date: 2025/01/26 16:42:44

Base Information

Drug NameAR-701 (Aridis Pharmaceuticals)
Drug Alias NameCOVID-19 Spike Glycoprotein Inhibitor/Angiotensin Converting Enzyme 2 Modulator (Aridis)Fully Human IgG1 mAbs (Aridis Pharmaceuticals)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAngiotensin-converting enzyme 2 modulatorsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoproteinAngiotensin-converting enzyme 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAridis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAridis Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A